Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1579-1588

  Bengtsson, Anders A ^a   Sturfelt, Gunnar ^a   Lood, Christian ^a   Rönnblom, Lars ^b   Van Vollenhoven, Ronald F ^c   Axelsson, Bengt ^d   Sparre, Birgitta ^d   Tuvesson, Helén ^d   Öhman, Marie Wallén ^d   Leanderson, Tomas ^d  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Active Biotech Research AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABR 215757; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA 1 ANTITRYPSIN; ALPHA INTERFERON; BILIRUBIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; FIBRINOGEN; HAPTOGLOBIN; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OROSOMUCOID; PAQUINIMOD; PARACETAMOL; PLACEBO; PREDNISOLONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; GLOMERULONEPHRITIS; HEADACHE; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MONOCYTE; MOUSE; MULTICENTER STUDY; MYALGIA; NEUTROPHIL COUNT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; TENDINITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANIMALS; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED MRL LPR; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; QUINOLINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860460054     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33493     Document Type: Article

References (36)

1. Rahman A, Isenberg DA,. Systemic lupus erythematosus. N Engl J Med 2008; 28: 929-39.
2. Jonsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3- quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47: 2075-88.
3. Bjork J, Kleinau S,. Paradoxical effects of LS-2616 (linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 1989; 27: 319-21.
4. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S,. Prevention of diabetes in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 1994; 37: 1195-201.
5. Hedlund G, Link H, Zhu J, Xiao BG,. Effects of linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. Int Immunopharmacol 2001; 1: 1123-30.
6. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Astrom M, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163-70.
7. Runstrom A, Leanderson T, Ohlsson L, Axelsson B,. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice. J Neuroimmunol 2006; 173: 69-78.
8. Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998; 41: 1040-6.
9. Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
10. Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwartz A, Linde A, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-6.
11. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, et al. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. Neurology 2000; 54: 1726-33.
12. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, et al. Linomide in relapsing and secondary progressive MS. Part II. MRI results. Neurology 2000; 54: 1734-41.
13. Tan IL, Lycklama a Njieholt GJ, Polman CH, Ader HJ, Barkhof F,. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase III trials. Mult Scler 2000; 6: 99-104.
14. Strandgarden K, Hoglund P, Nordle O, Polacek J, Wannman H, Gunnarsson PO,. Dissolution rate-limited absorption and complete bioavailability of roquinimex in man. Biopharm Drug Dispos 1999; 20: 347-54.
15. 14C) roquinimex after oral administration to healthy volunteers. Biopharm Drug Dispos 2000; 21: 53-67.
16. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T,. Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis. Neurology 2005; 64: 987-91.
17. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effects of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.
18. Jeffery DR,. Development of laquinimod for relapsing-remitting multiple sclerosis. Future Neurol 2008; 3: 641-8.
19. Lood C, Stenstrom M, Tyden H, Gullstrand B, Kallberg E, Leanderson T, et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R60.
20. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biology 2009; 7: 800-12.
21. Carlsten H, Jonsson C, Bokarewa M, Svensson L, Tarkowski A,. The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus. Int Immunopharmacol 2004; 4: 1515-23.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
23. Gladman DD, Ibanez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91.
24. Hua J, Kirou K, Lee C, Crow MK,. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-16.
25. Theofilopoulos AN, Dixon FJ,. Murine models for systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
26. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systematic lupus erythematosus: report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008; 67: 195-205.
27. Stoll ML, Gavalchin J,. Systemic lupus erythematosus: messages from experimental models. Rheumatology (Oxford) 2000; 39: 18-27.
28. Jonsson R, Tarkowski A, Backman K,. Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice. Agents Actions 1988; 25: 368-74.
29. Spetz-Hagberg AL, Larsson-Sciard EL,. Decreased levels of pathogenic IgG and anti-DNA antibodies in autoimmune mice after linomide treatment. Res Immunol 1989; 140: 517-25.
30. Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stalhandske T,. Successful treatment of autoimmunity in MRL/l mice with LS-2616, a new immunomodulator. Arthritis Rheum 1986; 29: 1405-9.
31. 1 hybrid mice. Immunology 1986; 59: 589-594.
32. Ronnblom L, Alm GV,. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003; 5: 68-75.
33. Ronnblom L, Eloranta ML, Alm GV,. The type I interferon system in systemic lupus erythematosus [review]. Arthritis Rheum 2006; 54: 408-20.
34. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-71.
35. Crow MK, Kirou KA, Wohlgemuth J,. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481-90.
36. Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M, Truedsson L, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116: 1951-7.